Cost-Effectiveness Analysis of MammaPrint ® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer.

testing to guide the use of endocrine therapy in our simulated patient population appears not to be a cost-effective strategy compared with usual care. The cost effectiveness of the test can be improved by reducing the price or preselecting a population more likely to benefit from the test.